Prof Charles Geyer speaks to ecancer at SABCS 2018 about the results of the phase III KATHERINE clinical trial.

He explains that the trial was designed to improve the improved invasive disease-free survival (IDFS) of HER2-positive early breast cancer patients who had residual disease after receiving neoadjuvant chemotherapy and trastuzumab.

Prof Geyer reports that substituting trastuzumab emtansine for adjuvant trastuzumab improved IDFS in patients with HER2-positive early breast cancer.

Watch his press conference here: [ Ссылка ]

Read more about this work here: [ Ссылка ]

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

свернуть